Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Chanan-Khan

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
Hematology/Oncology and Stem Cell Therapy|May 31, 2020
Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysisSonikpreet Aulakh, Tea Reljic, Farah Yassine, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2018
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple MyelomaSikander Ailawadhi, Kevin R Kelly, Robert A Vescio, et al.
Leukemia Research|September 12, 2006
Regular analgesic use and risk of multiple myelomaKirsten B Moysich, Mathew R Bonner, Gregory P Beehler, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 23, 2015
Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database ReviewJennifer A Crozier, Taimur Sher, Dongyun Yang, et al.
Cancer|April 28, 2011
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical responseAsher Chanan-Khan, Kena C Miller, David Lawrence, et al.
Cancers|November 27, 2021
Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age ReportingThejus Jayakrishnan, Sonikpreet Aulakh, Mizba Baksh, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Trends in Early Mortality From Multiple Myeloma: A Population-Based AnalysisVivek Kumar, Meghna Ailawadhi, Navnita Dutta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamideOwen A O'Connor, Emily A Smith, Lorraine E Toner, et al.
British Journal of Haematology|December 17, 2011
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent mannerAisha Masood, Kasyapa Chitta, Aneel Paulus, et al.
Blood|July 30, 2005
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)Asher Chanan-Khan, Kena C Miller, Kenichi Takeshita, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
Hematology/Oncology and Stem Cell Therapy|May 31, 2020
Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysisSonikpreet Aulakh, Tea Reljic, Farah Yassine, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2018
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple MyelomaSikander Ailawadhi, Kevin R Kelly, Robert A Vescio, et al.
Leukemia Research|September 12, 2006
Regular analgesic use and risk of multiple myelomaKirsten B Moysich, Mathew R Bonner, Gregory P Beehler, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 23, 2015
Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database ReviewJennifer A Crozier, Taimur Sher, Dongyun Yang, et al.
Cancer|April 28, 2011
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical responseAsher Chanan-Khan, Kena C Miller, David Lawrence, et al.
Cancers|November 27, 2021
Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age ReportingThejus Jayakrishnan, Sonikpreet Aulakh, Mizba Baksh, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Trends in Early Mortality From Multiple Myeloma: A Population-Based AnalysisVivek Kumar, Meghna Ailawadhi, Navnita Dutta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamideOwen A O'Connor, Emily A Smith, Lorraine E Toner, et al.
British Journal of Haematology|December 17, 2011
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent mannerAisha Masood, Kasyapa Chitta, Aneel Paulus, et al.
Blood|July 30, 2005
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)Asher Chanan-Khan, Kena C Miller, Kenichi Takeshita, et al.
Pageof 11